These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10123844)

  • 21. Efficacy and safety of teicoplanin in gram-positive pulmonary infections.
    Sanduzzi A; Nani E; Sarno M; Vatrella A; Parrella R; Mattiello A
    J Chemother; 1991 Jan; 3 Suppl 1():224-6. PubMed ID: 12041771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health economic issues in the treatment of drug-resistant serious Gram-positive infections.
    Nathwani D
    J Infect; 2009 Sep; 59 Suppl 1():S40-50. PubMed ID: 19766889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost of Gram-negative resistance.
    Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
    Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [First case of infection due to vancomycin resistant Enterococcus faecalis in New Caledonia].
    Garin B; Barny S; Lechevallier S; Agathe-Nerine J
    Med Mal Infect; 2006 May; 36(5):297-8. PubMed ID: 16631333
    [No Abstract]   [Full Text] [Related]  

  • 27. Dosage recommendations for teicoplanin.
    Wilson AP; Grüneberg RN; Neu H
    J Antimicrob Chemother; 1993 Dec; 32(6):792-6. PubMed ID: 8144419
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.
    Segreti J
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():29-35. PubMed ID: 15811022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.
    Mauldin PD; Salgado CD; Durkalski VL; Bosso JA
    Ann Pharmacother; 2008 Mar; 42(3):317-26. PubMed ID: 18285560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceuticals and medical devices: cost savings.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic burden of antimicrobial resistance.
    Maragakis LL; Perencevich EN; Cosgrove SE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug Reimbursement System--cost containment and patient advocacy].
    van der Kuy A
    TVZ; 1992 Apr; (7):249-51. PubMed ID: 1575931
    [No Abstract]   [Full Text] [Related]  

  • 34. Gram-positive infections: epidemiological aspects and trends of antibiotic resistance.
    Varaldo PE; Biavasco F; Montanari MP; Facinelli B
    J Chemother; 1991 Jan; 3 Suppl 1():158-62. PubMed ID: 12041754
    [No Abstract]   [Full Text] [Related]  

  • 35. Formulary can help hold down drug costs.
    Glazier HS; Berger S
    Mod Healthc; 1993 Apr; 23(17):38. PubMed ID: 10125671
    [No Abstract]   [Full Text] [Related]  

  • 36. [The efficacy of intraventricularly administered vancomycin in the case of central nervous system infection caused by enterococcus faecalis].
    Czaban SL; Lebkowski WJ; Krajewski JP; Borkowski J
    Wiad Lek; 2002; 55(9-10):617-25. PubMed ID: 12607418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A; Arthur M; Depardieu F; Chau F; Pouzet C; Courvalin P; Fantin B
    J Infect Dis; 2004 Jan; 189(1):90-7. PubMed ID: 14702158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal sepsis in hospital-born babies.
    Butt T; Ahmad RN; Usman M
    J Coll Physicians Surg Pak; 2004 Feb; 14(2):125; author reply 125-6. PubMed ID: 15228882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.